We Are Pro-Knowledge People And Knowledge Is Our Asset


Pragya Bioresearch is biopharmaceutical Research Company principally engaged in discovering and developing drugs for human health care through genetic engineering. Pragya Bioresearch is a scientifically advanced company with the tools, information and strategies for determining the medical impact of genes and genetic variations. Utilizing a novel population genetics approach, Pragya Bioresearch is systematically identifying potential disease-related genes that affect the most significant portions of the overall population.

By focusing on disease genes with a broad population impact, Pragya Bioresearch expects to play a critical role in bringing new therapeutic products to the market while maximizing the return on drug development. Our research and development activities are focused on market-oriented products to treat diabetes, infectious disease, inflammatory and autoimmune diseases, neurological disorders, cancer, fibrosis and congestive heart failure.

Pragya Bioresearch will make a distinguished position and set a new standard for leadership in the biopharmaceutical industry by discovering, developing, manufacturing, and marketing a continuing pipeline of medical therapies in years ahead.

The study of biology in 21st century has entered the "post-genomic" era. Latest development in genome will lead to more efficient identification of breakthrough biological molecules and targeted drug design from which the next generation of biopharmaceutical drugs will emerge.

Sequence, structure, and function are the order of the world for teams of scientists working in, what has been dubbed the post-genome era. With the completion of the human genome sequence--and the compilation of sequence data for many other organisms--work is underway on the next "big science" project in the life sciences: rapid determination of protein structures.

Pragya Bioresearch is intensifying its investment in leading genomic technologies with the goal of developing a pool of genetically selected leads to feed our biological research capability, and then applying multiple approaches to filter the growing amount of available information on gene structure into a strategic pool of promising genes.

Our strength and investment in this scientifically new area will enhance our research productivity, as the application of genomic creates multiple opportunities for breakthroughs in biological discovery. Pragya Bioresearch's genome research is lead by the Speed and Innovation of Biotechnology to become a leading Global Pharmaceutical Company.

A primary tool for discovery at Pragya Bioresearch remains the technology at the foundation of the biotechnology industry: recombinant DNA technology -- recombining DNA from different organisms to produce new organisms that can make proteins that may provide medical benefit. Experiments with organisms lacking a specific gene, and therefore a specific protein, unmask the roles of individual proteins in disease states. Each advance in technology and each improvement in the relationship between computer science and bioscience helps spur research advances toward important new medicines.

Scientists at Pragya Bioresearch use their unique backgrounds and skills to develop novel research areas. Currently, scientists understand the function and importance of only about 10 percent of the genes in the human genome. Next decade would be a time of challenges; we anticipate an extraordinary amount of new information will become available. Pragya Bioresearch, with its extraordinary capabilities in biological research, would be able to recognize which genes are therapeutically useful and commercially valuable. Our core research strength is the rapid discovery of new drug candidates by capitalizing on our biology expertise to accelerate the elucidation of gene function.

Our research strategy is our future business plan. Pragya Bioresearch is focused to following research areas, organized by the pathologies:

  • Diabetes
  • Inflammatory and autoimmune diseases
  • Neurological disorders
  • Oncology
  • Fibrosis
  • Congestive heart failure.